Navinci and SciLife enters collaboration: Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala.

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that…

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and…

Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market.

Uppsala and Luzern, September 2021. Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market.   ”Switzerland is an important market for Navinci and Lucerna-Chem is an excellent organization for us to partner with as they have a strong presence in the region, customer base, and network. We much look…

Proximity ligation: A revolutionary protein detection technology – Made in Uppsala

Cellular processes can only be understood as the dynamic interplay of molecules. This means that we need accurate techniques to monitor interactions of endogenous proteins directly in individual cells and tissues, to reveal the cellular and molecular architecture and its responses to disturbances. Protein detection with higher sensitivity and specificity is a constant need in…